利拉鲁肽联合二甲双胍对肥胖型T2DM患者的有效性及安全性评价

Effectiveness and Safety of Lilalutide Combined with Metformin in Obese T2DM Patients

目的:探讨利拉鲁肽联合二甲双胍治疗肥胖型T2DM的有效性及安全性。方法:回顾性分析2018年1月-2020年1月笔者所在医院100例肥胖型T2DM患者的临床资料,依据治疗方法的不同将其分为对照组(n=50)和研究组(n=50)。对照组采用单纯二甲双胍治疗,研究组采用利拉鲁肽联合二甲双胍治疗。比较两组体质量指数、血糖水平及不良反应发生情况。结果:治疗后,研究组体质量指数、空腹血糖、餐后2 h血糖、糖化血红蛋白均优于对照组,差异有统计学意义(P<0.05)。研究组不良反应发生率为6.0%(3/50),低于对照组的26.0%(13/50),差异有统计学意义(P<0.05)。结论:利拉鲁肽联合二甲双胍治疗肥胖型T2DM的效果显著,可有效改善患者血糖水平,降低不良反应发生率,安全性较好。

Objective:To investigate the effectiveness and safety of Lilalutide combined with Metformin in obese T2DM patients.Method:The clinical data of 100 obese T2DM patients in our hospital from January 2018 to January 2020 were retrospectively analyzed.According to different treatment methods,they were divided into the control group(n=50)and the study group(n=50).The control group was treated with Metformin alone,while the study group was treated with Lilarutide combined with Metformin.The body mass indexes,blood glucose level and adverse reactions were compared between the two groups.Result:After treatment,the body mass indexes,fasting blood glucose,2 h postprandial blood glucose,and glycosylated hemoglobin in the study group were all better than those in the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the study group was 6.0%(3/50),which was lower than 26.0%(13/50)in the control group,and the difference was statistically significant(P<0.05).Conclusion:Lilarutide combined with Metformin has a significant effect in the treatment of obese T2DM,which can effectively improve the blood glucose level of patients,reduce the incidence of adverse reactions,and has a good safety.